Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair

There is great demand for the development of novel therapies for ischemic cardiovascular disease, a leading cause of morbidity and mortality worldwide. We report here on the development of a completely synthetic cell-free therapy based on peptide amphiphile nanostructures designed to mimic the activity of VEGF, one of the most potent angiogenic signaling proteins. Following self-assembly of peptide amphiphiles, nanoscale filaments form that display on their surfaces a VEGF-mimetic peptide at high density. The VEGF-mimetic filaments were found to induce phosphorylation of VEGF receptors and promote proangiogenic behavior in endothelial cells, indicated by an enhancement in proliferation, survival, and migration in vitro. In a chicken embryo assay, these nanostructures elicited an angiogenic response in the host vasculature. When evaluated in a mouse hind-limb ischemia model, the nanofibers increased tissue perfusion, functional recovery, limb salvage, and treadmill endurance compared to controls, which included the VEGF-mimetic peptide alone. Immunohistological evidence also demonstrated an increase in the density of microcirculation in the ischemic hind limb, suggesting the mechanism of efficacy of this promising potential therapy is linked to the enhanced microcirculatory angiogenesis that results from treatment with these polyvalent VEGF-mimetic nanofibers.

[1]  S. Stupp,et al.  Capturing the stem cell paracrine effect using heparin‐presenting nanofibres to treat cardiovascular diseases , 2010, Journal of tissue engineering and regenerative medicine.

[2]  Allan S Hoffman,et al.  Injectable pH- and temperature-responsive poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers for delivery of angiogenic growth factors. , 2010, Biomacromolecules.

[3]  David J Mooney,et al.  Effects of VEGF temporal and spatial presentation on angiogenesis. , 2010, Biomaterials.

[4]  E. W. Meijer,et al.  Multivalent supramolecular dendrimer-based drugs. , 2010, Biomacromolecules.

[5]  J. A. Kessler,et al.  Emerging peptide nanomedicine to regenerate tissues and organs , 2010, Journal of internal medicine.

[6]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[7]  Jörn Tongers,et al.  Human studies of angiogenic gene therapy. , 2009, Circulation research.

[8]  C James Kirkpatrick,et al.  Dynamic in vivo biocompatibility of angiogenic peptide amphiphile nanofibers. , 2009, Biomaterials.

[9]  David Vance,et al.  The design of polyvalent scaffolds for targeted delivery. , 2009, Advanced drug delivery reviews.

[10]  D. Mooney,et al.  Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. , 2009, Biomaterials.

[11]  D. Czajkowsky,et al.  The human IgM pentamer is a mushroom-shaped molecule with a flexural bias , 2009, Proceedings of the National Academy of Sciences.

[12]  M. Merkx,et al.  High-affinity peptide-based collagen targeting using synthetic phage mimics: from phage display to dendrimer display. , 2009, Journal of the American Chemical Society.

[13]  S. Stupp,et al.  Light-triggered bioactivity in three dimensions. , 2009, Angewandte Chemie.

[14]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[15]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[16]  Shuguang Zhang,et al.  Designer functionalized self-assembling peptide nanofiber scaffolds for growth, migration, and tubulogenesis of human umbilical vein endothelial cells , 2008 .

[17]  R. Kane,et al.  Polyvalency: a promising strategy for drug design. , 2008, Biotechnology and bioengineering.

[18]  G. Colombo,et al.  Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide. , 2008, Chemistry.

[19]  Michael G. Fehlings,et al.  Self-Assembling Nanofibers Inhibit Glial Scar Formation and Promote Axon Elongation after Spinal Cord Injury , 2008, The Journal of Neuroscience.

[20]  David J Mooney,et al.  Integrated approach to designing growth factor delivery systems , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Seppo Ylä-Herttuala,et al.  Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. , 2007, Journal of the American College of Cardiology.

[22]  D J Mooney,et al.  Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis , 2007, Journal of thrombosis and haemostasis : JTH.

[23]  Samuel I Stupp,et al.  Heparin binding nanostructures to promote growth of blood vessels. , 2006, Nano letters.

[24]  Trevor Douglas,et al.  Viruses: Making Friends with Old Foes , 2006, Science.

[25]  C. Pedone,et al.  Peptide‐based Molecules in Angiogenesis , 2006, Chemical biology & drug design.

[26]  A. Hoffman,et al.  PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor , 2006, Journal of biomaterials science. Polymer edition.

[27]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[28]  D. Sorriento,et al.  Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  E. Chavakis,et al.  Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells , 2005, The Journal of experimental medicine.

[30]  S. Stupp,et al.  Probing the interior of peptide amphiphile supramolecular aggregates. , 2005, Journal of the American Chemical Society.

[31]  W. Schaper,et al.  Influence of Mechanical, Cellular, and Molecular Factors on Collateral Artery Growth (Arteriogenesis) , 2004, Circulation research.

[32]  Krista L. Niece,et al.  Selective Differentiation of Neural Progenitor Cells by High-Epitope Density Nanofibers , 2004, Science.

[33]  Martin Ehrbar,et al.  Cell‐demanded release of VEGF from synthetic, biointeractive cell‐ingrowth matrices for vascularized tissue growth , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  L. Claesson‐Welsh,et al.  VEGF receptor signal transduction. , 2003, Science's STKE : signal transduction knowledge environment.

[35]  J. Isner,et al.  Postnatal Recapitulation of Embryonic Hedgehog Pathway in Response to Skeletal Muscle Ischemia , 2003, Circulation.

[36]  William R. Wagner,et al.  Targeted In Vivo Labeling of Receptors for Vascular Endothelial Growth Factor , 2003, Circulation.

[37]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[38]  G. Fields,et al.  Characterization of peptide-amphiphiles possessing cellular activation sequences. , 2003, Biomacromolecules.

[39]  J. Isner,et al.  Stromal Cell–Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell Recruitment for Ischemic Neovascularization , 2003, Circulation.

[40]  Samuel I Stupp,et al.  Peptide-amphiphile nanofibers: A versatile scaffold for the preparation of self-assembling materials , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Hubbell,et al.  Covalently conjugated VEGF--fibrin matrices for endothelialization. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[42]  F. Sellke,et al.  Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.

[43]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[44]  F. Sellke,et al.  Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[45]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[46]  J. Isner,et al.  Mouse model of angiogenesis. , 1998, The American journal of pathology.

[47]  G M Whitesides,et al.  A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin. , 1998, Science.

[48]  R. Zivin,et al.  Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. , 1997, Chemistry & biology.

[49]  D. Baccanari,et al.  Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. , 1997, Science.

[50]  J. Folkman,et al.  A simple procedure for the long-term cultivation of chicken embryos. , 1974, Developmental biology.

[51]  A. Wear CIRCULATION , 1964, The Lancet.

[52]  Honggang Cui,et al.  Self‐assembly of peptide amphiphiles: From molecules to nanostructures to biomaterials , 2010, Biopolymers.

[53]  Samuel I Stupp,et al.  Development of bioactive peptide amphiphiles for therapeutic cell delivery. , 2010, Acta biomaterialia.

[54]  J. Folkman Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[55]  D. Nolte,et al.  Restoration of blood flow and evaluation of corresponding angiogenic events by scanning electron microscopy after a single dose of VEGF in a model of peripheral vascular disease , 2004, Angiogenesis.

[56]  Nasim Akhtar,et al.  Angiogenesis assays: a critical overview. , 2003, Clinical chemistry.

[57]  J. Gratton,et al.  Vascular Endothelial Growth Factor-dependent Down-regulation of Flk-1/KDR Involves Cbl-mediated Ubiquitination CONSEQUENCES ON NITRIC OXIDE PRODUCTION FROM ENDOTHELIAL CELLS* , 2003 .